Resistance

Resistance in your own words

• 

  My life with HIV

  I was born in Zambia in 1973 and came to England in April 1994 to live with my cousin to help her look after her...

  From: In your own words

Resistance news from aidsmap

• ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

  Treatment for HIV-positive individuals with persistent viral replication despite therapy with multiple regimens is effective and safe over two years when it omits nucleoside reverse transcriptase inhibitors (NRTIs), provided patients have three active alternative drugs available, according to research published ...

  13 June 2019 | Michael Carter

• Significant health gains from faster switching to second-line ART in sub-Saharan Africa

  Switching to second-line antiretroviral therapy (ART) after a single viral load measurement above 1000 copies/ml has the potential to save lives, avert a significant burden of AIDS-related illnesses and help achieve the 90-90-90 target, according to the results of a ...

  29 May 2019 | Michael Carter

• Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

  Virological response rates were excellent among patients receiving second-line antiretroviral therapy (ART) based on dolutegravir, even when regimens included a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) to which there was pre-existing resistance, according to research presented to the Conference on Retroviruses ...

  13 March 2019 | Michael Carter

• One in six South Africans drug resistant before starting HIV treatment

  One in six people not on treatment in a large South African household survey already had drug-resistant HIV and more than half of those on treatment had resistance to at least one drug, researchers reported last week at the ...

  11 March 2019 | Keith Alcorn

• How many people who have used PrEP get HIV the same year? New York study finds out

  One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently people start PrEP while unknowingly having HIV, often because they have acquired it so recently that they are still in the ‘window period’ when it cannot ...

  07 March 2019 | Gus Cairns

• South Africa reports successful third-line HIV treatment programme

  People with resistance to first- and second-line antiretroviral drugs can still achieve high rates of viral suppression in the first year on third-line regimens according to a South African study published in the January issue of the Journal of ...

  04 January 2019 | Esther Nakkazi

• How dangerous is gonorrhoea resistance and can it be halted?

  The bacterium that causes the common sexually transmitted infection (STI) gonorrhoea develops resistance to antibiotics easily, and some cases of multidrug-resistant gonorrhoea, originating from abroad, were reported from the UK this year, raising concerns that gonorrhoea could become untreatable. ...

  06 December 2018 | Gus Cairns

• Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

  The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual classes. Despite the overall success of antiretrovirals (ARVs), there remain a minority ...

  07 November 2018 | Gus Cairns

• Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds

  A study measuring HIV drug resistance at two timepoints in Kenyan patients on second-line, protease inhibitor-based regimens has found very high levels of drug resistance in people with detectable viral loads. Unexpectedly, it found higher rates of resistance in people with ...

  22 October 2018 | Gus Cairns

• Dolutegravir durable with high rates of viral suppression in people who experienced virological failure with older integrase inhibitors

  Antiretroviral regimens containing the integrase inhibitor dolutegravir are durable and achieve high rates of viral suppression in people who experienced virological failure with older integrase inhibitors, Italian investigators report in the Journal of Clinical Virology. The ...

  09 July 2018 | Michael Carter

More news

Resistance news selected from other sources

• Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

  "Public health (officials) should definitely be aware of the implications of drug resistance mutations conferring resistance to tenofovir and/or lamivudine on the activity, efficacy and durability of DTG in such a country, knowing that at present, individual- level HIV drug resistance testing in low and middle income countries (LMICs) is rare and that data are lacking on DTG use in settings with limited or no viral load monitoring."

  07 July 2019 | Medscape (free registration required)

• Genotype Testing at HIV Diagnosis Provides No Benefit

  For the majority of people with HIV in the US, the current treatment guidelines recommend an integrase strand inhibitor paired with an NRTI as first-line ART. Therefore, baseline genotype results currently guide the choice of initial NRTI pair, given transmitted NRTI resistance (NRTI-R). With this evolution of HIV treatment, the role and value of baseline genotype testing has become uncertain. This study determined the clinical and economic value of baseline genotype testing for people newly diagnosed with HIV in the US.

  25 June 2019 | Infectious Disease Advisor

• A Mysterious Infection, Spanning the Globe in a Climate of Secrecy

  The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa.

  08 April 2019 | New York Times

• Can high-dose dolutegravir be a rescue therapy?

  A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

  12 March 2019 | CATIE

• Should we be concerned some gay men are buying antibiotics online for STIs?

  A leading online provider of PrEP also sells the antibiotic doxycycline - but why are people buying it and why are health organizations concerned?

  28 December 2018 | Gay Star News

• Resistance to second-line ARTs increasing in South Africa

  An increasing number of HIV patients in the Western Cape and other parts of South Africa are experiencing resistance to second-line antiretroviral therapy (ART). The Star reports that this was revealed by the fifth South African National HIV Prevalence, Incidence, Behaviour and Communication Survey conducted last year by the Human Sciences Research Council (HSRC). The survey found resistance to ARVs in 27.4% of the respondents who were not virally suppressed.

  14 December 2018 | Medical Brief

• Uganda:15 Percent HIV-Positive Ugandans Resistant to Drugs - Report

  Nearly two in every 10 people living with HIV in Uganda are resistant to antiretroviral (ARVs) drugs, according to findings in a study report that Uganda Virus Research Institute (UVRI) released yesterday. This, the researchers said, requires them to switch to more expensive and scarce medicines.

  13 September 2018 | AllAfrica

• Ibalizumab Provides New Option for Patients with Multidrug-Resistant HIV

  A newly published phase 3 study of patients with multidrug-resistant (MDR) HIV shows that ibalizumab can be a safe and effective option for patients with limited other avenues of treatment.

  23 August 2018 | MD Magazine

• New HIV therapy reduces virus, boosts immunity in drug-resistant patients

  Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

  16 August 2018 | Science Daily

• Reported 'PrEP Failure' in Thailand May Be a Missed Acute HIV Infection: Here's What You Need to Know

  The Infectious Diseases Society of America reported on June 29, 2018, that a new HIV acquisition had been found in a person using pre-exposure prophylaxis (PrEP). According to the journal article, a 28-year-old cisgender male in Thailand began using PrEP on March 16, 2016, after being verified HIV negative by a third generation antibody test. However the third generation antibody test available in this case has a window period of three to 12 weeks, with 3% of the population still testing HIV negative after 12 weeks. This is why clinical testing sites use RNA testing whenever possible, as the RNA test from May 13 did show positive for HIV while the third generation antibody test on the same day showed HIV negative.

  17 July 2018 | TheBody PRO

More news